D.A. Davidson & CO. Sells 84 Shares of Cencora, Inc. (NYSE:COR)

D.A. Davidson & CO. lessened its position in Cencora, Inc. (NYSE:COR) by 4.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,892 shares of the company’s stock after selling 84 shares during the quarter. D.A. Davidson & CO.’s holdings in Cencora were worth $426,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in COR. New Millennium Group LLC purchased a new stake in Cencora in the 2nd quarter worth about $26,000. MFA Wealth Advisors LLC purchased a new stake in shares of Cencora in the second quarter worth approximately $30,000. Concord Wealth Partners bought a new stake in shares of Cencora during the 3rd quarter worth approximately $30,000. SYSTM Wealth Solutions LLC purchased a new position in Cencora during the 2nd quarter valued at $36,000. Finally, Ashton Thomas Securities LLC purchased a new position in Cencora during the 3rd quarter valued at $41,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

COR has been the subject of several research analyst reports. Bank of America reiterated a “neutral” rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Evercore ISI upped their price objective on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Leerink Partners dropped their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Barclays upped their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Insider Activity

In related news, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares of the company’s stock, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 93,018 shares of company stock valued at $22,478,942 in the last ninety days. Insiders own 15.80% of the company’s stock.

Cencora Stock Up 0.1 %

Cencora stock opened at $250.05 on Wednesday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a fifty-two week low of $195.83 and a fifty-two week high of $253.27. The company has a market cap of $49.27 billion, a PE ratio of 33.30, a PEG ratio of 1.66 and a beta of 0.45. The business’s 50-day simple moving average is $235.84 and its two-hundred day simple moving average is $233.00.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.88%. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. Cencora’s payout ratio is presently 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.